Who benefits from triple ruleout?

Article

Two groups of patients do not benefit from a CTA scan to rule out coronary artery disease, pulmonary embolism, and aortic dissection-the so-called triple ruleout, according to Dr. U. Joseph Schoepf, director of CT research and development at Medical University of South Carolina. One comprises those who, based on clinical judgment, will leave the hospital. Scanning these people simply increases costs and radiation exposure. The other consists of those who have clear ECG signs or enzyme elevations for myocardial infarction.

Two groups of patients do not benefit from a CTA scan to rule out coronary artery disease, pulmonary embolism, and aortic dissection-the so-called triple ruleout, according to Dr. U. Joseph Schoepf, director of CT research and development at Medical University of South Carolina. One comprises those who, based on clinical judgment, will leave the hospital. Scanning these people simply increases costs and radiation exposure. The other consists of those who have clear ECG signs or enzyme elevations for myocardial infarction.

Where the triple ruleout is valuable is in the gray zone: patients who have acute coronary syndrome but whose presentation is not clear-cut. They may have a nondiagnostic ECG or markers that come back negative. Without the triple ruleout, these individuals would be admitted for an extended period of observation. They would undergo serial ECGs, serial enzyme tests, and possibly other nuclear medicine tests or catheter angiography.

"If the coronary CT is negative, we can conclude that it excludes significant artery disease as a cause of acute chest pain. The negative predictive value is as high as 98% to rule out stenosis. With 64-slice CT, we are more confident than ever," Schoepf said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.